Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dacetuzumab
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Dacetuzumab is a humanized IgG1 monoclonal antibody that targets the CD40 antigen, which is highly expressed on various hematological malignancies including multiple myeloma, non-Hodgkin lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. It binds to the CD40 receptor and acts as a partial agonist without blocking CD40/CD40L interactions. Dacetuzumab induces tumor cell death through several mechanisms: direct induction of apoptosis via signal transduction, antibody-dependent cellular cytotoxicity (ADCC), and phagocytosis (ADCP). It also enhances immune effector functions against tumor cells. The drug was developed by Seattle Genetics (now Seagen) and licensed to Genentech for further development. Clinical trials were conducted in various hematologic cancers but development has been discontinued for these indications[1][2][3][4][6].
- Other names
- dacetuzumab
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on dacetuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dacetuzumab.